Table 2.

Clinical and biologic data at the time of kidney biopsy

CharacteristicsNumber
AKI according KDIGO criteria, n=23
 Stage 11 (4%)
 Stage 22 (9%)
 Stage 320 (87%)
Hypertension, n=2310 (43%)
uPCR, g/g, n=21/23a9.49 (range, 1.7–27)
Serum albumin level, g/dl, n=21/232.0 (range, 0.7–4)
Microscopic hematuria, n=21/23a10 (48%)
Leukocyturia, n=21/23a9 (43%)
Time between malaria infection and kidney biopsy, d, n=2324 d (range, 7–80)
Immunologic findings, n=23
 None20 (87%)
 IgGκ spike1 (4%)
 Cryo (type II)2 (9%)
Parvovirus B19 serology, n=14/23
 IgM+, IgG−4 (29%)
 IgM−, IgG+0 (0%)
 IgM+, IgG+0 (0%)
 IgM−, IgG−10 (71%)
ApoL1 status, n=7/23
 G1/G14 (57%)
 G1/G23 (43%)
  • KDIGO, Kidney Disease Improving Global Outcome; uPCR, urine protein-creatinine ratio; Cryo, cryoglobulinemia.

  • a Two patients with anuria.